Medical Policy

This document addresses gene therapy for spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement. Two gene therapy products,, Zolgensma^® (onasemnogene abeparvovec-xioi) and Itvisma^® (onasemnogene abeparvovec-brve), have been approved by the Food and Drug Administration (FDA).

Note: Please refer to clinical pharmacy criteria for information regarding other disease-modifying treatments for SMA; for example: nusinersen (Spinraza) or risdiplam (Evyrsdi).

Note: For a high-level overview of this document, please see “Summary for Members and Families” below. 

Medically Necessary:

A one-time infusion of onasemnogene abeparvovec-xioi is considered medically necessary in individuals with spinal muscular atrophy (SMA) when all of the following criteria are met:

1. Confirmed SMA diagnosis as documented by a bi-allelic SMN1 5q gene variant or deletions and either of the following:
   1. No more than 3 copies of SMN2; or
   2. Onset of SMA-associated signs and symptoms before 6 months of age;
      and
2. Less than two years of age at the time of vector infusion; and
3. Anti-adeno-associated viral vector, serotype 9 (AAV9) antibody titer less than or equal to 1:50; and
4. No use of invasive ventilatory support (tracheotomy with positive pressure) or use of non-invasive ventilator support (BiPAP) for more than 16 hours per day as a result of advanced SMA disease; and
5. No serious concomitant illness (for example, severe liver or kidney disease, symptomatic cardiomyopathy, active infection).

A one-time infusion of onasemnogene abeparvovec-brve is considered medically necessary in individuals with spinal muscular atrophy (SMA) when all of the following criteria are met:

1. Confirmed SMA diagnosis as documented by a bi-allelic SMN1 5q gene variant or deletions; and
2. No more than 3 copies of SMN2; and
3. Two years of age or older at the time of vector infusion; and
4. Anti-adeno-associated viral vector, serotype 9 (AAV9) antibody titer less than or equal to 1:50; and
5. None of the following:
   1. Prior receipt of Zolgensma^® (onasemnogene abeparvovec-xioi) or other gene therapy; or
   2. Current use of other survival motor neuron (SMN)-targeting therapies (for example nusinersen or risdiplam);
      and
6. No serious concomitant illness (for example, severe liver or kidney disease, symptomatic cardiomyopathy, diabetes, severe respiratory compromise, active but untreated infection); and
7. Documentation from the treating provider that SMA disease severity is not too advanced to likely derive benefit from treatment (for example, when complications of advanced SMA are present, including, but not limited to chronic assisted ventilator-support, dependency on enteral nutrition, severe contractures or scoliosis).

Investigational and Not Medically Necessary:

Onasemnogene abeparvovec-xioi and onasemnogene abeparvovec-brve are considered investigational and not medically necessary when the criteria above are not met, including for repeat infusions, and for all other indications.

This document describes clinical studies and expert recommendations, and explains whether gene therapy with onasemnogene abeparvovec (Zolgensma and Itvisma) may be appropriate. The following summary does not replace the medical necessity criteria or other information in this document. The summary may not contain all of the relevant criteria or information. This summary is not medical advice. Please check with your healthcare provider for any advice about your health.

Key Information

Zolgensma and Itvisma are two types of gene therapy designed to treat spinal muscular atrophy (SMA), a rare genetic condition that causes muscle weakness and breathing problems. Zolgensma is given through a single IV (intravenous) dose to children under 2 years old with specific genetic mutations linked to SMA. Itvisma is given through a spinal injection and is approved for people 2 years and older. These therapies aim to replace a faulty gene and help the body produce a protein needed for muscle function. Zolgensma works best when given early, before symptoms appear or within the first few months of life. Itvisma offers another option for older children but has shown more modest improvement. Both therapies carry risks, including liver problems, low platelet counts, and heart concerns, so patients need close monitoring after treatment.

What the Studies Show

Zolgensma has been studied in babies with 1 to 3 copies of a gene called SMN2. In babies with 1 or 2 copies, Zolgensma led to better survival and motor skills like sitting and walking, skills rarely seen without treatment. Children who received treatment earlier had better outcomes. Long-term studies showed that benefits lasted up to 6 years, although many children still needed help with feeding or breathing. Safety issues included liver damage, low blood platelets, and heart problems. In rare cases, children developed serious complications like liver failure or tumors. Fewer studies exist for children with 3 SMN2 copies, but most achieved key milestones such as walking. There is very limited data for children with 4 or more SMN2 copies or those older than 2.

Itvisma was studied in children and teens with 2 to 3 copies of SMN2. In the main study, children treated with Itvisma had small but statistically significant improvements in movement scores compared to those who received a sham treatment. Most side effects were mild or moderate, such as fever, vomiting, or liver test changes. Another study included children who had used other SMA treatments before Itvisma. These children also showed small gains in movement, especially if they had early-onset disease. No serious long-term safety issues were seen during the short follow-up. More studies are needed to understand how well Itvisma works over time and in broader groups of people with SMA.

When are Zolgensma and Itvisma Clinically Appropriate?

When is this not Clinically Appropriate?

The following have not been proven to improve health and are not considered clinically appropriate:

• Zolgensma or Itvisma in people with advanced SMA, such as complete limb paralysis or permanent ventilator use. Studies have not tested these treatments in such cases.
• Repeat doses of either Zolgensma or Itvisma, as they have only been tested as one-time treatments.
• Zolgensma in children older than 2 years or with 4 or more SMN2 copies. These groups were not included in clinical trials, and better studies are needed to know if Zolgensma improves health for them.
• Itvisma in people with 4 or more SMN2 copies. This group has not been studied, so possible benefits and harms are unknown.

(Return to Description/Scope)

Summary

Zolgensma (onasemnogene abeparvovec-xioi) is an FDA-approved gene replacement therapy indicated for children under two with spinal muscular atrophy (SMA) caused by bi-allelic SMN1 mutations. Administered as a one-time intravenous infusion, Zolgensma demonstrated significant improvements in survival and motor function, particularly when given presymptomatically or before 6 months of age. Across multiple clinical trials (Phase I, III STRIVE, STRIVE-EU, and the SPRINT study), infants with 1 to 3 SMN2 copies achieved key motor milestones like sitting and walking, which are rarely seen in natural disease progression. Follow-up data up to 6.2 years show sustained motor gains and survival benefits, although some participants experienced adverse events such as hepatotoxicity, thrombocytopenia, and cardiac issues. Post-marketing safety data further underscore the need for careful monitoring, with rare but severe events including liver failure and development of neoplasms. Limited data exists for people older than 2 years or with 4 or more SMN2 copies, though early real-world evidence in heavier, older children suggests potential but modest functional improvement.

In 2025, the FDA approved Itvisma (onasemnogene abeparvovec-brve), an intrathecal formulation of the same gene therapy, for SMA patients aged two and older. The STEER trial, a double-blind, sham-controlled study, demonstrated a statistically significant but modest improvement in motor function (HFMSE scores) in treated non-ambulatory children aged 2-17 with 2 to 4 SMN2 copies. Safety profiles were generally favorable, with most adverse events mild to moderate and including pyrexia, vomiting, and hepatotoxicity. The open-label STRENGTH trial broadened inclusion to patients previously treated with nusinersen or risdiplam, confirming tolerability and showing slight functional gains, especially in those with early-onset disease. While Itvisma offers a treatment option for older children previously excluded from Zolgensma trials, the magnitude of clinical benefit appears modest, and longer-term studies are needed to determine durability and broader efficacy.

Discussion

Zolgensma (onasemnogene abeparvovec-xioi)

Zolgensma (onasemnogene abeparvovec-xioi) was approved by the FDA on May 24, 2019, for the treatment of individuals less than 2 years of age with SMA who have bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. The product was approved for single intravenous administration only; repeat administration of Zolgensma and its use in individuals with advanced SMA (for example, need for permanent ventilatory support or complete limb paralysis) have not been evaluated. In clinical trials, the product was known by its former name, AVXS-101.

The FDA approval cites data on the efficacy of Zolgensma in a total of 36 treated individuals. This includes 15 individuals in a completed Phase I open-label, single-arm, ascending-dose clinical trial and 21 individuals in an, at the time, ongoing Phase III trial (using the higher dose in the Phase I trial). Both trials required a confirmed diagnosis of SMA based on gene mutation analysis with bi-allelic SMN1 mutations, either 1 or 2 copies of SMN2, and symptom onset at 6 months of age and earlier, consistent with SMA type 1. Trials also required administration of infusion at 6 months of age or younger (although a single study participant in the Phase I high-dose cohort was older than 6 months of age at study entry [7.9 months]; this individual achieved the fewest major milestones assessed in the study cohort). At the time of treatment, the mean age of individuals was 3.4 months (range 0.9 to 7.9 months) in the high-dose group of the Phase I trial (Mendell, 2017) and 3.9 months (range 0.5 to 5.9 months) in the Phase III trial (Zolgensma product label, 2021).

SMA with Two Copies of SMN2 (and/or onset of SMA before 6 months of age)

Mendell and colleagues (2017) published data from the Phase I trial on Zolgensma (NCT02122952). The study involved the infusion of a single dose of the therapy in individuals with genetically confirmed SMA type 1 and 2 copies of SMN2 who experienced onset of symptoms between birth and 6 months of age. To be eligible for participation, individuals were required to have hypotonia, a delay in motor skills, poor head control, round shoulder posture and joint hypermobility. Exclusion criteria included presence of active viral infection (HIV, hepatitis B or C), invasive ventilatory support or with pulse oximetry less than 95% saturation, persistent anti-AAV9 antibody titer (≥ 1:50), concomitant illness that in the opinion of the Principal Investigator created unnecessary risks for gene transfer, concomitant use of drugs for treatment of myopathy or neuropathy, drugs used to treat diabetes mellitus, or ongoing immunosuppressive therapy or immunosuppressive therapy within 3 months of starting the trial, abnormal clinically significant laboratory values (GGT > 3XULN, bilirubin ≥ 3.0 mg/dL, creatinine ≥ 1.8 mg/dL, Hgb < 8 or > 18 g/Dl; WBC > 20,000 per cmm), and signs of aspiration based on a swallowing test with an unwillingness to use an alternative to oral feeding.

In the Phase I trial, individuals received 1 of 2 doses of AVXS-101, 6.7 x 10¹³ vg/kg (low-dose) or 2.0 x 10¹⁴ vg/kg (high-dose). The low-dose cohort included 3 individuals who were treated at a mean age of 6.3 months (range, 5.9 to 7.2 months) whereas the high-dose cohort included 12 individuals treated at a mean age of 3.4 months (range, 0.9 to 7.9 months). All but 1 individual in the high-dose cohort were treated prior to 6 months of age. Mean age of symptom onset ranged from 0 to 3 months. Concomitant treatment with Spinraza (nusinersen) did not occur during the study. The primary study outcome was safety in terms of the rate of treatment-related serious adverse events (SAEs) that were grade 3 or higher. The primary efficacy endpoint was time until death or the need for permanent ventilatory assistance, which was defined as needing ventilation at least 16 hours a day for at least 14 consecutive days. The secondary efficacy outcome was change in the Children’s Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP INTEND) score, a 16-item 64-point scale that assesses motor function and attainment of significant developmental milestones including the ability to sit unassisted and roll over unassisted. Maintenance of scores over 40 points on the CHOP INTEND is considered to be clinically meaningful for individuals with SMA (Mendell, 2017). As reported by Mendell and colleagues (2017), at the data cutoff of August 7, 2017, all 15 individuals were alive and without need for permanent ventilator assistance at 20 months of age (compared with a historical rate of survival of 8%). At baseline, none of the individuals in the low-dose cohort had achieved any motor milestones and individuals in the high-dose cohort had not achieved any motor milestone other than bringing a hand to the mouth. As of August 2017, the majority of individuals in the high-dose cohort, and none in the low-dose cohort had achieved at least one major motor milestone. A total of 11 individuals in the high-dose cohort sustained CHOP INTEND scores of more than 40 points. Earlier gene therapy infusion appeared to be associated with higher changes in scores for motor function as assessed by CHOP INTEND scores. A single study participant was older than 6 months of age at study entry (7.9 months); this individual achieved the fewest major milestones assessed in the study cohort. A total of 56 SAEs were observed in 13 individuals. Of these, two events were considered treatment-related; both involved elevated levels of aspartate aminotransferase (ALT) and aspartate aminotransferase (AST). Mendell et al. (2017, supplemental materials) noted that evidence from neurophysiological and animal studies supports the mechanistic importance of therapeutic intervention before motor neuron death, and hence emphasizes the importance of early intervention with Zolgensma to rescue neurons.

Mendell and colleagues (2020) reported 5-year follow-up in a long-term extension of the Phase I trial. A total of 13 of the original 15 individuals were enrolled in the extension study, all 3 members of the low-dose cohort and 10 of 12 individuals from the high-dose cohort. At the data cutoff date for this publication, maximum follow-up was 6.2 years after treatment. At least 1 SAE was reported in 8 individuals (62%), 1 from the low-dose cohort and 7 from the high-dose cohort. The most frequently reported SAEs were acute respiratory failure (4 events), pneumonia (4 events), dehydration (3 events), respiratory distress (2 events) and bronchiolitis (2 events). All SAEs were considered by investigators to be unrelated to Zolgensma therapy. At a mean follow-up time of 5.2 (range, 4.6 to 6.2) years after dosing, all 3 individuals in the low-dose cohort were alive and 2 of these were not on permanent ventilation. All 10 individuals in the high-dose cohort were alive and did not require permanent ventilation. In the high-dose cohort, all motor milestones that were previously attained were maintained and 2 of the 10 attained a video-confirmed motor milestone of standing with assistance. As of the data cutoff date, 7 of the 13 individuals were receiving concomitant nusinersen.

Trials have excluded individuals with AAAV9 antibody titers > 1:50, serious concomitant illness, and dependence on ventilatory support (tracheotomy with positive pressure or use of non-invasive ventilator support [BiPAP] for more than 16 hours per day [Phase I]). As stated above, the trials on which FDA approval was based including individuals with a diagnosis of SMA documented by bi-allelic SMN1 mutations, either 1 or 2 copies of SMN2, and symptom onset by at 6 months of age. No studies have been published evaluating concurrent treatment with nusinersen.

A Phase III open-label single-arm trial known as STRIVE, conducted in the United States, was published in 2021 by Day and colleagues. A similar study, STRIVE-EU, conducted in Europe, was published in 2021. These studies included individuals with and a diagnosis of SMA type 1 with 1 or 2 copies of SMN2. In addition, individuals needed to be less than 6 months old at the time of enrollment. The trial evaluated the dosage used in the commercial onasemnogene abeparvovec-xioi product, which was the higher dose used in the Phase 1 trial. Eligibility criteria in the European study were similar to the U.S. STRIVE study, except individuals requiring non-invasive ventilatory support for less than 12 hours a day or who required feeding support were included in STRIVE-EU. A total of 22 individuals were enrolled in the STRIVE trial at a mean age of 3.7 months (standard deviation [SD], 1.6 months). Before treatment, none of them required non-invasive ventilator (NIV) support and all were able to feed exclusively orally and swallow thin liquids. At 18 months of age, 13 of 22 (59%) individuals achieved the co-primary endpoint of independent sitting for at least 30 seconds. An additional individual was able to sit for at least 30 seconds at the 14-month visit but was uncooperative at 18 months. For the other co-primary endpoint, 20 of 22 (91%) individuals survived without permanent ventilation at 14 months. Mean increases from baseline in the CHOP INTEND score were 11.7 points at 3 months and 14.6 points at 6 months. At some timepoint in the study, 21 individuals (95%) achieved a CHOP INTEND score of at least 40 points, which the authors noted is unusual for children with SMA type 1. They noted that 1 enrolled individual died of respiratory distress; the death was considered to be unrelated to treatment. Also, 3 participants had treatment-related SAEs, 2 cases of elevated hepatic aminotransferases and 1 case of hydrocephalus.

In the STRIVE-EU study, at baseline, 9 of 33 individuals (27%) required ventilator support, 9 (27%) received feeding support and 5 (15%) received both ventilator and feeding support. There was 1 individual who was excluded from the intention to treat (ITT) analysis due to being dosed at 181 days. A total of 14 of 32 individuals (44%) in the ITT analysis achieved the primary endpoint of functional independent sitting for at least 10 seconds. The endpoint was achieved at a median age of 15.9 months. For the secondary outcome, 31 of 32 individuals (97%) survived free from permanent ventilator support at 14 months. As in the U.S. STRIVE study, study participants achieved improvements in the CHOP INTEND score. Mean improvement in scores from baseline were 10.3 points at 3 months and 13.6 points at 6 months, and 24 individuals (73%) achieved a CHOP INTEND score of at least 40 points. One death occurred among study participants, and this was determined to be unrelated to treatment. A total of 32 participants (97%) had at least one AE and 6 (18%) participants had a treatment-related SAE.

SMA with Three Copies of SMN2

Individuals with up to three copies of SMN2 were studied in the Phase III single-arm SPRINT study. Participants were individuals with a genetic diagnosis of SMA and no clinical evidence of disease (for instance, presymptomatic). Study findings were published separately for the individuals with two (2022a) and three (2022b) copies of SMN2 (2022b). Children with the SMN2 gene modifier variant (c.859 G>C) (which is associated with a milder disease course) could enroll in the study, but those with the SMN2 gene modifier variant would not be included in the ITT population. None of the 29 infants enrolled (14 in the 2-copy cohort and 15 in the 3-copy cohort) had a c.859 G>C modifier variant. Participants received a one-time single infusion of onasemnogene abeparvovec at no later than 6 weeks of age. All participants took oral prednisolone starting at least 1 day prior to infusion to attenuate the inflammatory response to AAV9. The primary efficacy outcome was the ability to sit for at least 30 seconds through 18 months of age in the 2-copy cohort and the ability to stand independently for at least 3 seconds at up to 24 months of age in the 3-copy cohort. In the 2-copy cohort, the secondary endpoints were survival at 14 months, defined as the avoidance of death or avoidance of requiring permanent ventilation (tracheostomy or at least 16 hours daily respiratory assistance for at least 14 consecutive days in the absence of an acute reversible illness, excluding in the perioperative period) and the ability to maintain body weight at or above the 3^rd percentile at all visits without the need for feeding support at any visit up to 18 months. In the 3-copy cohort, the secondary efficacy endpoint was the ability to walk alone at any visit up to 24 months, and exploratory endpoints were survival at 14 months of age and the ability to maintain body weight at or above the 3^rd percentile without the need for feeding support at any visit up to 24 months. Findings were compared to those of children in the historical Pediatric Neuromuscular Clinical Research (PNCR) cohort which described the natural course of SMA type 1.

As reported by Strauss (2022a), the 14 infants in the 2-copy cohort were infused with onasemnogene abeparvovec at a median of 21 days of life (range, 8 to 34 days). All 14 of them achieved the primary efficacy endpoint of independent sitting for at least 30 seconds at any visit up to 18 months of age. None of the children in the historical PNCR cohort achieved this milestone. Of the 12 children who were assessed at the 18-month visit, all were able to sit independently for at least 30 seconds at that visit. In terms of secondary endpoints, all 14 children were alive and free of permanent ventilation at 14 months (compared with 6 of 23 in the historical PNCR cohort). None of the children in the cohort required any type of mechanical respiratory support during the trial. Of the 14 children, 13 maintained a body weight at or above the 3^rd percentile without the need for feeding support throughout the trial. There were a total of 159 treatment-emergent adverse events (TEAEs); each participant experienced at least 1 TEAE and 5 reported a serious TEAE. Ten children had a TEAE considered by the investigator to be related to the study treatment and none of these was serious. Of the TEAE of special interest, 3 children experienced hepatotoxicity, 3 experienced thrombocytopenia, 2 experienced a cardiac AE, 3 experienced sensory abnormalities suggestive of ganglionopathy and 2 experienced thrombotic microangiopathy. The investigator considered only 2 events, thrombocytopenia and platelet count decrease, as possibly related to treatment and both events were resolved within a week.

Strauss (2022b) reported on the 15 infants in the 3-copy cohort of the SPRINT trial. All participants were infused with onasemnogene abeparvovec at a median of 32 days of life (range, 9 to 43 days). All 15 children achieved the primary efficacy endpoint for this cohort, which was independent standing for at least 3 seconds at any visit up to 24 months of age. This milestone was achieved at a median age of 377 days, and all children retained this milestone at the 23-month study visit. In comparison, in the historical PNCR cohort only 24% of children with SMA achieved independent standing. Fourteen of the 15 (93%) children walked independently for at least five steps up to 24 months, compared with 21% of children in the PNCR cohort. Participants walked independently at a median age of 422 days. None of the children in the 3-copy cohort required mechanical respiratory support of any kind throughout the trial. There were a total of 166 TEAEs; each participant experienced at least 1 TEAE and 3 children reported a serious TEAE. Eight children (53%) had a TEAE considered by the investigator to be related to the study treatment and none of these was serious. Of the TEAE of special interest, 4 children experienced hepatotoxicity, 2 experienced thrombocytopenia, 3 experienced a cardiac AE and 1 experienced a sensory abnormality suggestive of ganglionopathy. The investigator considered all the hepatotoxicity events to be related to treatment and considered the cardiac AE to be possibly or probably related to treatment.

Latzer and colleagues (2023) reported on 25 children who were treated with Zolgensma at 1 of 4 centers in Israel. All study participants had genetically confirmed SMA, categorized as type I or II, and had 2 or 3 copies of the SMN2 gene. The median age of the children was 6.1 months at the time of treatment (interquartile range [IQR], 3.3 to 17 months). Eight of the children had received nusinersen prior to Zolgensma treatment; the remainder of the participants were treatment naïve. A total of 23 of 25 participants had baseline assessment by the CHOP-INTEND prior to Zolgensma treatment. Individuals who received gene therapy prior to 8 months of age had significantly greater improvement in motor function scores between baseline and last follow-up compared with those who received it after age eight months (median increase of 18 points compared to 8 points, p=0.002). None of the study participants lost motor function ability after gene therapy. A total of 11 individuals developed the ability to crawl and 7 developed the ability to walk (3 without assistance). Prior to treatment 3 individuals required enteral feeding; 1 of these was partially able to feed orally after treatment. An additional 4 individuals lost the ability to feed orally after treatment. Before receiving gene therapy, 5 individuals required noninvasive ventilatory support for 13 ± 1.7 hours per day. At last follow-up, 12 individuals required noninvasive ventilatory support for a median of 12 (IQR, 11.5 to 16) hours per day. None of the participants required invasive ventilatory support but 1 participant died 6 months after receiving gene therapy after experiencing complications from a severe respiratory illness.

SMA with Four or More Copies of SMN2

To date, there is a lack of data on Zolgensma treatment in individuals with 4 or more copies of SMN2. Blaschek and colleagues (2022) reported on 15 individuals with SMA and four copies of the SMN2 gene, 8 of whom used presymptomatic therapy. However, none of these individuals were treated with Zolgensma; treatments used were either nusinersen or risdiplam.

Post-marketing efficacy and safety data

Efficacy and safety data from the industry sponsored RESTORE registry were published by Servais and colleagues in 2024. Individuals with SMA were recruited worldwide for inclusion in the registry. As of the data cutoff of May 23, 2022, 168 individuals with SMA treated with onasemnogene abeparvovec in 7 countries were included in the registry. A total of 138 of the 168 individuals (82%) of individuals were from the United States. The median age at SMA diagnosis was 1 month (interquartile range [IQR], 0 to 6 months) and the mean age at Zolgensma infusion was 3 months (IQR, 1 to 10 months). A total of 80 of the 168 (48%) individuals had 2 copies of SMN2 and 70 (42%) had 3 copies of SMN2. The mean time from infusion to last known follow-up visit was 13.7 months (SD, 9.8 months, range 0 to 37 months). Event-free survival, defined as the avoiding death or permanent ventilatory support, was reported by SMN2 copy number. Permanent ventilatory support meant requiring a tracheostomy or respiratory support for 16 or more hours per day for 14 or more days, in the absence of acute reversible illness. In individuals with 2 copies of SMN2, event-free survival was 93.7% at 1 year and 90% at 2 years. For individuals with 3 copies of SMN2, 1-year event-free survival was 100%; 2-year event-free survival was not reported for this sub-group. The authors reported that there were insufficient data to report event-free survival for individuals with 1 SMN2 copy or with 4 or more SMN2 copies. Safety data were available for 167 of the 168 individuals with SMA treated with onasemnogene abeparvovec; 81 (49%) of these experienced at least 1 treatment-emergent AE. AEs of special interest included 49 cases (29.3%) of hepatotoxicity, 23 cases (13.8%) of transient thrombocytopenia, 22 (13.2%) cases of cardiac events and 1 case (0.6%) of thrombotic microangiopathy.

In 2024, Ruggiero and colleagues reported post-marketing safety data on onasemnogene abeparvovec from the European pharmacovigilance database. The analysis included 661 Individual Case Safety Reports (ICSRs) describing 2744 AEs. In over 92.1% of case reports, onasemnogene abeparvovec was the only reported suspected drug. Among these 2744 AEs, 1185 (43.1%) were non-serious, 558 (21.5%) caused or prolonged hospitalization, 118 (4.3%) were life-threatening and 130 (4.7%) resulted in death. The 130 AEs related to fatal outcomes were included in 39 individual case reports. In 3 of the 39 cases, nusinersen was a suspected drug along with onasemnogene abeparvovec. The fatal outcomes included 8 cases of cardiac arrest, 5 cases of respiratory arrest or respiratory failure and 4 cases of acute hepatic failure. One neoplasm was reported, a malignant astrocytoma.

Regarding safety, previously acute liver injury resulted in death in 2 individuals who were treated with  onasemnogene abeparvovec, as reported by Phillipidis (2022). In 2023, Gaillard and colleagues reported 2 cases of necrotizing enterocolitis following Zolgensma infusion in infants who were identified by newborn screening to have SMA, and Retson and colleagues (2023) reported 1 case of epithelioid neoplasm of the spinal cord approximately 14 months after treatment with Zolgensma. In the case of epitheloid neoplasm, an onasemnogene abeparvovec nucleic acid signal was detected in one of the tumor cells.

McMillian (2025) published data from the first 12 months of the SMART trial, a phase 3B open label multicenter cohort study. A total of 24 ambulatory and non-ambulatory participants with SMA mean 4.7 years (18 months to approximately 9 years), any number of SMN2 copies, anti-AAV9 antibody titer ≤ 1:50, not requiring invasive ventilation, free of serious concomitant illness, and weighing ≥ 8.5 kg and ≤ 21 kg were included in the study. The purpose of the trial was to evaluate the use of onasemnogene abeparvovec in a population of subjects in this body weight range. The participants were stratified by ≥ 8.5-13, > 13-17, and > 17-21 kg groups. All participants received a single IV dose onasemnogene abeparvovec (1.1 × 1014 vector genomes [vg]/kg). Three of the participants were naive to SMA treatment and the remainder (n=21) had received previous SMA disease-modifying treatment with either nusinersen or risdiplam. SMA type 1 was reported in 8 participants, type 2 in 11, and type 3 in 5. Two copies of the SMN2 gene were reported in 5 participants, 3 copies in 18, and 4 or more in 1. With regard to developmental motor milestones, at baseline, 21 participants (88%) sat without support, 10 (42%) demonstrated hands-and-knees crawling, 9 (38%) demonstrated pulls-to-stand, 7 (29%) stood with assistance and walked with assistance, 6 (25%) stood alone, and 6 (25%) walked alone. With regard to AEs, no deaths and no AEs leading to discontinuation from the study were reported, but all participants had at least 1 TEAE, one of which was considered related to onasemnogene abeparvovec. The most frequent TEAEs were vomiting (63%), pyrexia (33%), nausea (33%), hypertransaminasemia (29%), and decreased platelet count (25%). Out of a total of 15 fifteen participants had SAEs, with 7 having SAEs treatment related, including thrombocytopenia (13%) and vomiting (8%). AEs of special interest (AESI) were reported in 23 participants (96%), including hepatotoxicity (83%), thrombocytopenia (71%), and cardiac AEs (13%). While the incidence of hepatotoxicity was high, characterized by increased transaminases (ALT or AST), most cases were mild or moderate. Severe events were reported in 17% (n=4/24) of participants, but all participants were asymptomatic. By the end of the 12 moth follow-up period, 67% of participants had an ALT value greater than the upper level of normal, and 8% had an AST value greater than upper level of normal. For other AESI, 71% of participants experienced transient thrombocytopenia, with most cases reported as mild or moderate and asymptomatic. Additionally, three participants experienced a cardiac AESI, including 1 case each of bradycardia, nocturnal dyspnea, and electrocardiogram evidence of T wave inversion. Again, all cases were considered mild, and none were considered related to treatment. Secondary outcomes, as measured by the Hammersmith Functional Motor Scale-Expanded (HFMSE), were reported for 20 participants (83.3%), all who were > 24 months of age at baseline. The majority of the participants in all 3 weight groups achieved improvements from baseline in their HFMSE score during the study, with median increases in HFMSE total score of 4.0 (range, −5 to 11) at week 26 and 4.0 (range, −5 to 11) at week 52. Overall, at 12 months 18 participants had an increase in HFMSE score and 2 had a decrease in HFMSE score. However, only 11 participants (61%) with increased HFMSE score were reported to have a clinically meaningful increase of ≥3 points. Broken down by weight category, n=3 in the 8.5-13 kg group, n=3 in the >13-17 kg group, and n=5 in the >17-21 kg group. Of the two participants with decreased scores, 1 was in the 8.5-13 kg group and 1 was in the >13-17 kg group. Revised Upper Limb Module (RULM) data at 12 months were available for 17 participants, all of whom were ≥30 months of age at baseline and the majority had stable or improved total scores during the study. At week 52, 41% of participants had a clinically meaningful increase of ≥3 points in RULM total score (n=3 in the 8.5-13 kg group, n=4 in the >17-21 kg group). Two participants (12%) had a decrease in RULM total score of ≤3 points at week 52 (n=2 in the >17-21 kg group. At baseline, all participants demonstrated head control and sitting with support. Only 3 participants lost previously demonstrated developmental motor milestones at 12 months (n=1 baseline age 5.1 years in the >13-17 kg group; n=1 baseline age 3.1 years in the >13-17 kg group; n=1, baseline age 5.4 years in the >17-21 kg group). Two of these participants lost the ability to sit without support for 30 seconds, and the other lost the ability to walk with assistance. At 12 months, 4 participants achieved new developmental milestones during the study (n= 2 in the 8.5-13 kg group, n=1 in the >13-17 kg group, and n=1 in the >17-21 kg group), including standing with assistance (n=3), walking with assistance (n=2), and standing alone (n=1). This study includes a population of participants older than 2 years of age and one that had more than 3 copies of the SMN2 gene, and focuses on individuals with higher body weight, all factors not well studied in prior trials. The results for these populations are promising, demonstrating stabilization or improvement in most participants over a 12 month period. However, the study methodology, including lack of a control group, blinding, longer follow-up period, small number of participants overall and in each study group, and others impair the generalizability of these findings. Further investigation in these populations is needed.

Other Considerations

The published clinical trials use a single dose of gene therapy. Zolgensma is expected to represent a one-time treatment, given that development of AAV antibodies following gene therapy may limit the possibility of re-dosing or re-treating individuals. In the Phase I trial, 1 subject did not pass screening owing to the presence of anti-AAV9 antibody. Given that re-treatment may not be possible, establishing treatment durability and appropriate participant selection is important.

There are a number of open questions regarding Zolgensma therapy for SMA. The long-term durability of Zolgensma remains unknown, with the longest follow-up reported in published studies currently being 5 years. While the magnitude of treatment effect induced by Zolgensma appears sufficient to result in clinically meaningful motor function (as represented by a 40-point threshold as evaluated by the CHOP INTEND scores), it does not appear that treatment of individuals with SMA type 1 restores them to a healthy, non-diseased phenotype.

Treatment of individuals with SMA types 2 and 3 also remains under investigation; given the relatively stable clinical course of SMA types 2 and 3, with outcome differences related to the number of SMN2; additional SMN expression in older SMA individuals is less likely to have a significant clinical effect (Mendell, 2017 supplemental materials). Given that SMA is an irreversible, neurodegenerative disease, gene therapy may have a greater therapeutic impact early in the disease process. Also, given that the gene transfer viral doses for older individuals based on body weight is much greater, risks associated with larger dosing remain unknown (Mendell, 2017 supplemental materials).

In 2020, a working group within CURE SMA, a non-profit patient advocacy organization, published a letter to the editor recommending expansion of the criteria for SMA treatment (Glascock, 2020). The working group recommended immediate treatment of infants diagnosed with SMA via newborn screening who have up to four copies of survival motor neuron gene 2 (SMN2), based on the premise that individuals with three or four copies of SMN2 demonstrate a variable disease phenotype. Limited data (Feldkotter, 2002) suggests that a minority of individuals with four copies of SMN2 may develop a SMA phenotype consistent with SMA type 1 or 2 (1.6% and 14%, respectively), whereas about 5% of individuals with three SNM2 copies develop type 1 disease (60% develop type 2 and 35% develop type 3 disease) (Cusco, 2020). However, disease-modifying treatment (including Zolgensma) for pre-symptomatic SMA infants with four copies of SMN2 remains unstudied, and there are no data available to assess the potential benefits and harms of such treatment in this group of individuals. Onset of SMA-associated signs and symptoms before 6 months of age, irrespective of SMN2 copy number, is currently consistent with the Position Statement noted above.

Itvisma (onasemnogene abeparvovec-brve)

On November 25, 2025, the FDA approved an intrathecal preparation of onasemnogene abeparvovec, which Novartis branded Itvisma, for “the treatment of SMA in adult and pediatric patients 2 years of age and older with confirmed mutation in SMN1 gene”. The product was approved for single intrathecal administration only; repeat administration of Itvisma and its use in individuals with advanced SMA (for example, need for permanent ventilatory support or complete limb paralysis) have not been evaluated. In clinical trials, the product was known by its former name, OAV101 IT.

The FDA approval primarily cites data on the efficacy of Itvisma from the of the STEER trial, referred to as ‘Study 1’ in the label (NCT05089656; Proud, 2025). The STEER trial was a multicenter, double-blind, sham-controlled RCT involving 126 otherwise healthy, non-ambulatory participants age 2-17 years of age with confirmed bi-allelic SMN1 5q gene mutations, onset of SMA-associated signs and symptoms at or after 6 months of age, with anti-adeno-associated viral vector serotype 9 (AAV9) antibody titer less than or equal to 1:50, naive (historical or current use) for all SMN-targeting therapies (e.g., risdiplam [Evrysdi] and nusinersen [Spinraza]), and able to receive intrathecal therapy. Participants were assigned in a 3:2 fashion to treatment with either Itvisma (n=75) or a sham control procedure (n=51). The investigators also stratified participants into two age groups, 2 to < 5 years and 5 to < 18 years. In the younger group, 42 participants received Itvisma and 29 received the control treatment, In the older group, 33 received Itvisma and 22 received the control treatment. At the completion of the 52-week follow-up period, full data was available for 122 participants (96.8%), 72 (96%) in the Itvisma group and 50 (98%)  in the control group. The majority of participants had 3 SMN2 copies (94.4% overall, 97.3% for the Itvisma group and 90.2% for the control group). Participants with 2 SMN2 copies were identified in both groups, with 5 overall (4%), 1 on the Itvisma group and 4 in the control group. Four of more SMN2 copies were identified in 1 participant in each group (1.6% overall). Mean age at time of administration was 5.88 years overall, 5.89 years (3.58; range, 2.1-16.6) in the Itvisma group and 5.87 (3.05; range, 2.4-14.2) years for the control group. The authors reported that the study met the primary efficacy endpoint, change from baseline in HFMSE score at the end of 52 week study period, assessed using the initial α level of 0.01. The results demonstrated a 2.39-point improvement in HFMSE score for the Itvisma group compared to 0.51 point improvement in the control group (least squares mean [LSM] difference, 1.88 [95% confidence interval: 0.51−3.25]; p=0.0074). The improvement in the Itvisma group was noted as early as week 4 and maintained throughout the follow-up period. They reported no statistically significant differences between groups with regard to the secondary endpoints, achievement of at least a 3-point improvement in HFMSE score in the total study population, change from baseline in HFMSE score in participants < 5 years of age, achievement of at least a 3-point improvement in HFMSE score in participants < 5 years of age, and overall change from baseline in RULM. There were no significant between-group differences with regard to AEs. In the Itvisma group the incidence of AEs was 97.3% compared to 90.2% in the control group. For SAEs, the incidence in the Itvisma group was 28.0% compared to 33.3% in the control group. AEs of special interest (AESI) were reported in 16.0% of Itvisma participants and 13.7% of control participants. The most frequent AEs were upper respiratory tract infection and transient pyrexia. The most frequent SAEs were pneumonia (12.0% in the Itvisma group vs. 13.7% in the control group), vomiting (4.0% vs. 0%, respectively), pneumonia (12.0% vs. 13.7%, respectively), and lower respiratory tract infection (2.7% vs. 7.8%, respectively). AESI reported in the study included hepatotoxicity (9.3.0% in the Itvisma group vs. 9.8% in the control group), signs or symptoms that may be suggestive of dorsal root ganglia (DRG) toxicity (2.7% vs. 2.0%, respectively) and transient thrombocytopenia (5.3% vs. 3.9% , respectively). No AESI of malignancies, thrombotic microangiopathy, or cardiac AEs were reported for either group. All AESI were mild or moderate in intensity, none were severe or assessed to be an SAE, and all resolved during the follow-up period. Signs and symptoms that may be suggestive of DRG toxicity were reported for 3 participants, 2 in the Itvisma group (both 16 years) and 1 in the control group (a 7.9-year old). The Itvisma group participants reported sensory symptoms, which nerve conduction studies revealed decreasing sensory nerve action potential (SNAP) amplitudes with relative preservation of conduction velocities in distributions consistent with sensory symptoms. In the first Itvisma participant, symptoms began 20-days post-dose, with stabilization of symptoms in the feet and resolution of symptoms in the hands reported approximately 6 months post-dose with medical treatment. The second Itvisma participant experienced paresthesia in the feet at 17 days post-dose that stabilized at 52 weeks with medical treatment. The control participant reported paresthesia of the left thigh and progressing to the rest of their body 154 days after sham procedure. Their symptoms were mild and resolved after 15 days, without treatment. These results indicate a significant benefit or intrathecal onasemnogene abeparvovec-brve. However, the short follow-up period leaves uncertainty regarding assessment of delayed AEs or the benefit in motor function. Participants were provided with an opportunity to participate in a long-term continuation study (NCT05335876).

The FDA label also briefly describes data from the open label STRENGTH trial, referred to as ‘Study 2’ (NCT05386680; Kwon 2025). The STRENGTH trial involved 27 participants and was intended to assess the safety and tolerability of Itvisma across a wider spectrum of individuals with SMA than the STEER trial. The participants were otherwise healthy, non-ambulatory participants 2-17 years of age with confirmed bi-allelic SMN1 5q gene mutations, onset of SMA-associated signs and symptoms before 18 months of age, with anti-adeno-associated viral vector serotype 9 (AAV9) antibody titer less than or equal to 1:50, naive to hematopoietic or solid organ transplant, and able to receive intrathecal therapy. Unlike the STEER trial, STRENGTH trial participants were allowed to have had prior SMA therapy with nusinersen and risdiplam, which had to have been discontinued. The majority of participants had 3 SMN2 copies (n=23, 85.2%) and the remainder had 2 copies (n=4, 14.8%). No participant had 4 or more SMN2 copies. Two participants (7.4%) discontinued the study after Itvisma administration, 1 on day 106 and the other on day 273, due to guardian decision. The mean age at Itvisma administration was 7.4 (3.35; range, 2.4-17.7) years. Nusinersen had been discontinued for 21 participants (77.8%), discontinuation of risdiplam was reported for 4 participants (14.8%) and 2 who had previously received both nusinersen and risdiplam (7.4%). All participants reported experiencing at least one AE, with the most frequent being nasopharyngitis (n=15, 55.6%), pyrexia (n=14, 51.9%) and vomiting (n=13, 48.1%). AEs considered to be related to study treatment occurred in 13 participants (48.1%), including vomiting (n=6, 22.2%), headache (n=4, 14.8%) and pyrexia (n=3, 11.1%). SAEs were reported for 4 participants (n=4, 14.8%) and included infections and infestations system organ class (n=3, 11.1%) and most of which were respiratory infections (Table 2 and Supplementary Table 1). No AEs leading to death or study discontinuation were reported. AESI included transient thrombocytopenia (n=8, 29.6%), hepatotoxicity (n=4, 14.8%) and signs and symptoms that may be suggestive of dorsal root ganglia (DRG) toxicity (n=2, 7.4%). The most frequently reported AEs in the transient thrombocytopenia category were epistaxis (n=3, 11.1%) and contusion (n=2, 7.4%). All of these were considered non-serious, mild or moderate in intensity and resolved during the trial period. Hepatotoxicity AESI included increased levels of liver enzymes (n = 4, 14.8%) in participants 2−10 years of age. And were considered mild to moderate in intensity, non-serious and resolved with prednisolone treatment. Signs and symptoms that may be suggestive of DRG toxicity included one transient, mild and non-serious case of paresthesia in feet (n=1). The other case was considered not related to OAV101 IT, was transient, mild and non-serious sensory disturbance on forearms, neck and scalp (n=1). The mean change from baseline to week 52 in HFMSE score was 0.17 (2.89; range, -5.5 to 7.5), and the least squares mean (LSM) change from baseline to week 52 was 1.05 (standard error [s.e.], 0.61; 95% confidence interval [CI]: -0.21 to 2.32; Cohen’s d: 0.36). The mean change from baseline to week 52 in RULM score was 0.29 (2.85; range, --6.0 to 6.0), and the LSM change from baseline to week 52 was 0.59 (s.e., 0.55; 95% CI: -0.56 to 1.73). The authors reported a post-hoc analyses of HFMSE change from baseline for participants with age at symptom onset of 6 months or younger (n=6) compared with participants with age at symptom onset after 6 months (n=15). No between-group differences were reported. The results of this uncontrolled, unblinded study indicated some benefit to individuals with SMA with early onset of symptoms and those that have failed prior medical therapy with nusinersen and risdiplam. Additional long-term investigation is warranted to confirm that these findings are durable and clinically meaningful.

Other Considerations

As noted above with discussion of Zolgensma, there are a number of open questions regarding Itvisma therapy for SMA, including long-term durability, treatment of phenotypically milder forms of SMA (including treatment in individuals with 4 or more copies of SMN2), and treatment of individuals who may be too debilitated to derive benefit from disease-modifying therapies (for example, receiving chronic assisted ventilator-support, dependent on enteral nutrition, or with severe contractures or scoliosis).

SMA is a neuromuscular disorder that is characterized by degeneration of motor neurons of the spinal cord and brainstem. This degeneration results in progressive muscle weakness and atrophy. Atrophy occurs especially in the muscles that control the mouth, throat and respiration. Common complications of SMA include growth failure, restrictive lung disease, scoliosis, joint contractures and sleep disorders (Prior, 2016). SMA is the most common genetic cause of childhood death.

SMA is most often (96% of cases) caused by mutations in the survival motor neuron 1 (SMN1) gene, located on chromosome 5q13.2, which lead to deficiency in SMN protein (Verhaart, 2017). The inheritance pattern of chromosome 5q-related SMA is autosomal recessive. The different forms of 5q-SMA are caused by biallelic deletions or mutations in the SMN1 gene on chromosome 5q13.2. The most common mutation of the SMN1 gene is a deletion of exon 7; approximately 94 percent of individuals with clinically typical SMA carry homozygous deletions of exon 7. While the most common forms of SMA are caused by deletions or mutations in the SMN1 gene on chromosome 5q, there are a number of rare genetically and clinically heterogeneous non-5q spinal muscular atrophies. The SMN2 gene, which is nearly identical to the SMN1 gene, produces a low level (approximately 10%) of full-length function SMN protein and can modify the severity of SMA (Parente, 2018). The number of SMN2 copies ranges from zero to five, and the presence of three or more copies has been found to correlate with a milder form of SMA (Prior, 2016). Individuals with SMA type 1 are predicted to have two copies of the SMN2 gene (Butchbach, 2006). Defects in SMN2 alone do not appear to cause SMA (Verhaart, 2017). However, the correlation between the copy number of the SMN2 gene and the phenotype is not an exact correlation and may be related to other phenotypic modifiers, such as the presence of the variants c.859G>C in exon 7 and A-44G, A-549G, and C-1897T in intron 6 of SMN2 that act as positive modifier. For example, a case series of 450 Brazilian subjects found that those with specific pathogenic variants (c.460C>T and c.5C>G) presented a milder phenotype, and the SMN2 copy number did not correlate with disease severity (Mendonça, 2020).

The clinical phenotype of SMA ranges from mild to severe. SMA type 0 is most severe and SMA type 4 is least severe. SMA type 1 (also known as Werdnig-Hoffman disease) is the most common type representing about 60% of SMA diagnoses.

Table 1: Clinical Classification of Spinal Muscular Atrophy

Adapted from Butchbach, 2016 and Verhaart, 2017

The incidence of SMA is approximately 1 in 10,000 births (Parente 2018; Verhaart, 2017). Incidence rates by SMA type are estimated at 5.5, 1.9 and 1.7 per 100,000 births for SMA type 1, 2 and 3, respectively (Verhaart, 2017). The prevalence of all types of SMA is about 1 to 2 per 100,000. Due to the short life expectancy, the prevalence of SMA type 1 is approximately 0.04 to 0.28 per 100,000. The prevalence of SMA type 2 and SMA type 3 combined is estimated at about 1.5 per 100,000 (Verhaart, 2017). The median survival time for individuals with SMA type 1 is 7.4 months and, in pathophysiological studies, younger age of onset was significantly predictive of earlier death (Farrar, 2013).

Until recently, SMA was diagnosed clinically when individuals presented with symptoms such as hypotonia (low muscle tone) and weakness. With the advent of genetic testing, newborn screening for SMA has become more common and, on July 2, 2018, it was added to the list of newborn screening tests recommended by the U.S. government (HRSA, 2018). Individual states, however, make the final decision on whether or not to add SMA screening to their newborn panels. Prenatal carrier screening for SMA is also available but the degree of uptake is not clear.

A 2007 international consensus statement discussed standards of care for individuals with SMA (Wang, 2007). At that time, no SMA-specific treatments were available and the primary approach to care was managing manifestations of the disease. This includes acute and chronic respiratory illness management (for example., immunization, airway clearance, non-invasive ventilation), nutrition management (for example, supplementation, gastrostomy), orthopedic care (for example., orthotics, mobility aids, orthopedic surgery) and palliative care.

The first medication specifically developed for SMA, nusinersen (Spinraza) was approved by the FDA in 2016. Nusinersen, administered intrathecally (injected into the spine), is an SMN2-directed antisense oligonucleotide (ASO) designed to treat SMA caused by chromosome 5q mutations by increasing production of full-length SMN protein (Spinraza product label, 2016). Subsequently, the oral medication Evrysdi (risdiplam), an SMN2 splicing modifier, was approved by the FDA in August 2020 as a treatment of SMA in individuals aged 2 months and older (Risidiplam product label, 2020).

Gene replacement therapy introduces or alters genetic material to replace the function of a missing or dysfunctional gene with the goal of lessening or eliminating a disease process that results from genetic dysfunction. A gene may be altered using a carrier or “vector” which is often, but not always, a virus that has been modified to remove disease-causing genes, or DNA may be changed using genome (gene) editing, a group of technologies that allows genetic material to be added, removed, or altered. There are different approaches to gene therapy including replacing a mutated gene with a healthy gene, inactivating a mutated gene not functioning correctly, or introducing a new gene. Gene therapy has been under development for decades but has suffered many setbacks over the years.

Novartis has developed two gene therapies, Zolgensma and Itvisma, to treat SMA type 1. These therapies use a non-replicating adeno-associated virus (AAV) as a vector. A functional copy of the SMN1 gene is inserted into the vector and the therapy is delivered intravenously in the case of Zolgensma and intrathecally for Itvisma. The goal of therapy is to induce SMN expression in the treated individual’s motor neurons. Zolgensma is able to cross the blood-brain barrier where it targets motor neuron cells (the therapeutic target of most interest, as well as other central nervous system neurons at all regions of the spinal cord); however, Zolgensma can affect any tissue in the body. This may be of interest, given that the SMN protein is expressed by all cells and SMA1 affects multiple systems (for example, autonomic and enteric nervous systems, cardiovascular system, and pancreas), along with many cell types (for example, heart, pancreas, and skeletal muscle); however, the clinical significance of inducing SMN expression outside the central nervous system is unknown. Itvisma, since it is administered intrathecally, may avoid extra central nervous system complications.

Uncertainty remains regarding the extent to which gene therapy represents a permanent “cure”. There are also general uncertainties regarding long-term effectiveness and safety that pertain to gene replacement strategies as a therapeutic class.

Warnings and Precautions

Warnings from the FDA PI Label for Zolgensma (2023) include the following:

• Systemic Immune Response: Administer ZOLGENSMA to patients who are clinically stable in their overall baseline health status (e.g., hydration and nutritional status, absence of infection) prior to infusion. (5.2)
• Thrombocytopenia: Monitor platelet counts before ZOLGENSMA infusion, and at least weekly for the first month and then every other week for the second and third month until platelet counts return to baseline. (2.3, 5.2)
• Thrombotic Microangiopathy (TMA): If clinical signs, symptoms and/or laboratory findings occur, consult a pediatric hematologist and/or pediatric nephrologist immediately to manage as clinically indicated. (5.3)
• Elevated Troponin-I: Monitor troponin-I before ZOLGENSMA infusion, and weekly for the first month and then monthly for the second and third month until troponin-I level returns to baseline. (2.3, 5.3)
• AAV Vector Integration and Risk of Tumorigenicity: There is a theoretical risk of tumorigenicity due to integration of AAV vector DNA into the genome. Report cases of tumors in patients who received ZOLGENSMA, to Novartis Gene Therapies, Inc. (5.6, 17)

In addition, the Zolgensma label includes the following boxed warning, which was updated in February 2023:

• Cases of acute liver failure with fatal outcomes have been reported. Acute serious liver injury and elevated aminotransferases can also of occur with ZOLGENSMA. (5.1)
• Patients with preexisting liver impairment may be at higher risk. (5.1)
• Prior to infusion, assess liver function of all patients by clinical or examination and laboratory testing. Administer systemic corticosteroid to all patients before and after ZOLGENSMA infusion. Continue to monitor liver function for at least 3 months after infusion, --- and at other times as clinically indicated. (2.1, 2.3)

Furthermore, the label notes:

• The safety and effectiveness of repeat administration of ZOLGENSMA have not been evaluated.
• The use of ZOLGENSMA in patients with advanced SMA (e.g., complete paralysis of limbs, permanent ventilator dependence) has not been evaluated.

Use in Specific Populations

Pediatric use: Use of ZOLGENSMA in premature neonates before reaching full term gestational age is not recommended because concomitant treatment with corticosteroids may adversely affect neurological development. Delay ZOLGENSMA infusion until full-term gestational age is reached. (8.4)

Warnings from the FDA PI Label for Itvisma (2023) include the following

• Hepatotoxicity: Prior to ITVISMA injection, assess liver function of patients by clinical examination and laboratory testing. Continue to monitor liver function for at least 3 months after injection, and at other times as clinically indicated. (2.1, 2.4, 5.1)
• Thrombocytopenia: Monitor platelet counts before ITVISMA injection, and at least weekly for the first month and as clinically indicated until platelet counts return to baseline. (2.1, 2.4, 5.2)
• Peripheral Sensory Neuropathy: Consider complete neurologic evaluation and other testing and/or symptom management based on the patient's clinical presentation. (5.3)
• Thrombotic Microangiopathy (TMA): Prompt attention to signs and symptoms of TMA is advised, as TMA can result in life-threatening or fatal outcomes. If clinical signs, symptoms and/or laboratory findings occur, consult a hematologist and/or nephrologist immediately to manage as clinically indicated. (5.4)
• Elevated Cardiac Troponin I: Increases in cardiac troponin I have occurred following ITVISMA injection. Consider cardiac evaluation after ITVISMA administration and consult a cardiologist as needed. (5.5)
• AAV Vector Integration and Risk of Tumorigenicity: There is a theoretical risk of tumorigenicity due to integration of AAV vector DNA into the genome. Report cases of tumors in patients who received ITVISMA, to Novartis Gene Therapies, Inc. (5.6)

In addition, the Itvisma label includes the following boxed warning:

• Acute serious liver injury and elevated aminotransferases can occur with ITVISMA. (5.1)
• Patients with preexisting liver impairment may be at higher risk (5.1)
• Prior to intrathecal injection, assess liver function by clinical examination and laboratory testing. Administer systemic corticosteroid before and after ITVISMA injection. Continue to monitor liver function for at least 3 months after injection, and at other times as clinically indicated. (2.1, 2.4)

Adeno-associated virus (AAV): A small virus that infects humans and is not known to cause disease. Modified (non-replicating) AAVs are frequently used as viral vectors for gene therapy.

Autosomal recessive disorder: An inherited condition for which two copies of an abnormal gene must be present in order for the disease or trait to develop.

Gene replacement therapy: A medical treatment that introduces or alters genetic material to replace the function of a missing or dysfunctional gene with the goal of lessening or eliminating a disease process that results from genetic dysfunction.

SMN1 and SMN2: Genes that provide instructions for making the survival motor neuron (SMN) protein.

SMA Type 1: also known as infantile spinal muscular atrophy or Werdnig-Hoffmann disease. Onset of symptoms typically presents after birth but before age 6 months. Individuals with SMA type 1 have defects in the SMN1 gene and are predicted to have two copies of the SMN2 gene.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

When services may be Medically Necessary when criteria are met:

When services are Investigational and Not Medically Necessary:
For the procedure and diagnosis codes listed above when criteria are not met or for all other diagnoses not listed; or when the code describes a procedure indicated in the Position Statement section as investigational and not medically necessary.

Peer Reviewed Publications:

1. Bischof M, Lorenzi M, Lee J, et al. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1. Curr Med Res Opin. 2021; 37(10):1719-1730.
2. Blaschek A, Kölbel H, Schwartz O, et al. Newborn screening for SMA - can a wait-and-see strategy be responsibly justified in patients with four SMN2 copies? J Neuromuscul Dis. 2022; 9(5):597-605.
3. Butchbach ME. Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases. Front Mol Biosci. 2016; 3:7.
4. Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021; 20(4):284-293.
5. Farrar MA, Park SB, Vucic S, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017; 81(3):355-368.
6. Farrar MA, Vucic S, Johnston HM, et al. Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatr. 2013; 162(1):155-159.
7. Feldkötter M, Schwarzer V, Wirth R, et al. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002; 70(2):358-368.
8. Gaillard J, Gu AR, Neil Knierbein EE. Necrotizing enterocolitis following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J Pediatr. 2023;260:113493.
9. Glascock J, Sampson J, Connolly AM, et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2. J Neuromuscul Dis. 2020; 7(2):97-100.
10. Kwon JM, Munell F, Le Goff L, et al. Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial. Nat Med. 2025; Dec 8. Epub ahead of print.
11. McMillan HJ, Baranello G, Farrar MA, et al.; SMART Study Group. Safety and efficacy of iv onasemnogene abeparvovec for pediatric patients with spinal muscular atrophy: the phase 3b SMART study. Neurology. 2025; 104(2):e210268.
12. Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-year extension results of the Phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021; 78(7):834-841.
13. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Eng J Med. 2017; 377(18):1713-1722.
14. Mendonça RH, Matsui C Jr, Polido GJ, et al. Intragenic variants in the SMN1 gene determine the clinical phenotype in 5q spinal muscular atrophy. Neurol Genet. 2020; 6(5):e505.
15. Mercuri E, Muntoni F, Baranello G, et al. STR1VE-EU study group. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021; 20(10):832-841.
16. Parente V, Corti S. Advances in spinal muscular atrophy therapeutics. Ther Adv Neurol Disord. 2018; 11:1756285618754501.
17. Philippidis A. Novartis confirms deaths of two patients treated with gene therapy zolgensma. Hum Gene Ther. 2022; 33(17-18):842-844.
18. Proud CM, Vũ DC, Wilmshurst JM, et al.; STEER Study Group. Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial. Nat Med. 2025; Dec 8. Epub ahead of print
19. Retson L, Tiwari N, Vaughn J, et al. Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec. Mol Ther. 2023; 31(10):2991-2998.
20. Ruggiero R, Balzano N, Nicoletti MM, et al. Real-world safety data of the orphan drug Onasemnogene Abeparvovec (Zolgensma^®) for the SMA rare disease: a pharmacovigilance study based on the EMA adverse event reporting system. Pharmaceuticals (Basel). 2024; 17(3):394.
21. Servais L, Day JW, De Vivo DC, et al. Real-world outcomes in patients with spinal muscular atrophy treated with Onasemnogene Abeparvovec monotherapy: findings from the RESTORE registry. J Neuromuscul Dis. 2024; 11(2):425-442.
22. Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022a; 28(7):1381-1389.
23. Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022b; 28(7):1390-1397.
24. Tokatly Latzer I, Sagi L, Lavi R, et al. Real-life outcome after gene replacement therapy for spinal muscular atrophy: a multicenter experience. Pediatr Neurol. 2023; 144:60-68.
25. Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017; 12(1):124.
26. Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007; 22(8):1027-1049.

Government Agency, Medical Society, and Other Authoritative Publications:

1. Cuscó I, Bernal S, Blasco-Pérez L et al. Practical guidelines to manage discordant situations of SMN2 copy number in patients with spinal muscular atrophy. Neurol Genet. 2020; 6(6):e530.
2. Health Resources and Services Administration (HRSA). Recommended uniform screening panel. Last Reviewed July 2024. Available at: https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/index.html. Accessed on December 11, 2025.
3. Itvisma product label November 2025. Available at: https://www.fda.gov/media/189857/download?attachment. Access on December 11, 2025
4. Prior TW, Leach ME, Finanger E. Spinal Muscular Atrophy. Last updated September 19, 2024. GeneReviews^® Available at: http://www.ncbi.nlm.nih.gov/books/NBK1352. Accessed on December 11, 2025.
5. Risdiplam product label. Last updated February 2022. Available at: https://www.gene.com/download/pdf/evrysdi_prescribing.pdf. Accessed on December 11, 2025.
6. Spinraza product label. Last updated April 2024. Available at: https://www.spinrazahcp.com/content/dam/commercial/spinraza/hcp/en_us/pdf/spinraza-prescribing-information.pdf. Accessed on December 11, 2025.
7. Zolgensma product label. Last updated February 2025. Available at: https://www.novartis.com/us-en/sites/novartis_us/files/zolgensma.pdf. Accessed on December, 2025.

1. National Organization for Rare Disorders (NORD). Spinal Muscular Atrophy. Last updated: April 17, 2024. Available at: https://www.rarediseases.org/rare-diseases/spinal-muscular-atrophy/. Accessed on December 10, 2025.
2. U.S. National Library of Medicine Genetics Home Reference. Spinal Muscular Atrophy. Last updated October 1, 2018. Available at: https://medlineplus.gov/genetics/condition/spinal-muscular-atrophy/ Accessed on December 10, 2025.

AveXis
AVXS-101
Itvisma
onasemnogene abeparvovec-xioi
onasemnogene abeparvovec-brve
Zolgensma

The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association